Altered dietary salt intake for preventing diabetic kidney disease and its progression.

Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

Publication: 2004- : Chichester, West Sussex, England : Wiley
Original Publication: Oxford, U.K. ; Vista, CA : Update Software,

Diabetic Nephropathies*/prevention & control ; Diabetes Mellitus, Type 1* ; Hypertension*/drug therapy ; Renal Insufficiency, Chronic*/prevention & control ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/prevention & control; Humans ; Sodium Chloride, Dietary/adverse effects ; Sodium

Background: There is strong evidence that our current consumption of salt is a major factor in the development of increased blood pressure (BP) and that a reduction in our salt intake lowers BP, whether BP levels are normal or raised initially. Effective control of BP in people with diabetes lowers the risk of strokes, heart attacks and heart failure and slows the progression of chronic kidney disease (CKD) in people with diabetes. This is an update of a review first published in 2010.
Objectives: To evaluate the effect of altered salt intake on BP and markers of cardiovascular disease and of CKD in people with diabetes.
Search Methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 31 March 2022 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.
Selection Criteria: We included randomised controlled trials (RCTs) of altered salt intake in individuals with type 1 and type 2 diabetes. Studies were included when there was a difference between low and high sodium intakes of at least 34 mmol/day.
Data Collection and Analysis: Two authors independently assessed studies and resolved differences by discussion. We calculated mean effect sizes as mean difference (MD) and 95% confidence intervals (CI) using the random-effects model. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Main Results: Thirteen RCTs (313 participants), including 21 comparisons (studies), met our inclusion criteria. One RCT (two studies) was added to this review update. Participants included 99 individuals with type 1 diabetes and 214 individuals with type 2 diabetes. Two RCTs (four studies) included some participants with reduced overall kidney function. The remaining studies either reported that participants with reduced glomerular filtration rate (GFR) were excluded from the study or only included participants with microalbuminuria and normal GFR. Five studies used a parallel study design, and 16 used a cross-over design. Studies were at high risk of bias for most criteria. Random sequence generation and allocation concealment were adequate in only three and two studies, respectively. One study was at low risk of bias for blinding of participants and outcome assessment, but no studies were at low risk for selective reporting. Twelve studies reported non-commercial funding sources, three reported conflicts of interest, and eight reported adequate washout between interventions in cross-over studies. The median net reduction in 24-hour urine sodium excretion (24-hour UNa) in seven long-term studies (treatment duration four to 12 weeks) was 76 mmol (range 51 to 124 mmol), and in 10 short-term studies (treatment duration five to seven days) was 187 mmol (range 86 to 337 mmol). Data were only available graphically in four studies. In long-term studies, reduced sodium intake may lower systolic BP (SBP) by 6.15 mm Hg (7 studies: 95% CI -9.27 to -3.03; I² = 12%), diastolic BP (DBP) by 3.41 mm Hg (7 studies: 95% CI -5.56 to -1.27; I² = 41%) and mean arterial pressure (MAP) by 4.60 mm Hg (4 studies: 95% CI -7.26 to -1.94; I² = 28%). In short-term studies, low sodium intake may reduce SBP by 8.43 mm Hg (5 studies: 95% CI -14.37 to -2.48; I² = 88%), DBP by 2.95 mm Hg (5 studies: 95% CI -4.96 to -0.94; I² = 70%) and MAP by 2.37 mm Hg (9 studies: 95% CI -4.75 to -0.01; I² = 65%). There was considerable heterogeneity in most analyses but particularly among short-term studies. All analyses were considered to be of low certainty evidence. SBP, DBP and MAP reductions may not differ between hypertensive and normotensive participants or between individuals with type 1 or type 2 diabetes. In hypertensive participants, SBP, DBP and MAP may be reduced by 6.45, 3.15 and 4.88 mm Hg, respectively, while in normotensive participants, they may be reduced by 8.43, 2.95 and 2.15 mm Hg, respectively (all low certainty evidence). SBP, DBP and MAP may be reduced by 7.35, 3.04 and 4.30 mm Hg, respectively, in participants with type 2 diabetes and by 7.35, 3.20, and 0.08 mm Hg, respectively, in participants with type 1 diabetes (all low certainty evidence). Eight studies provided measures of urinary protein excretion before and after salt restriction; four reported a reduction in urinary albumin excretion with salt restriction. Pooled analyses showed no changes in GFR (12 studies: MD -1.87 mL/min/1.73 m², 95% CI -5.05 to 1.31; I² = 32%) or HbA1c (6 studies: MD -0.62, 95% CI -1.49 to 0.26; I² = 95%) with salt restriction (low certainty evidence). Body weight was reduced in studies lasting one to two weeks but not in studies lasting for longer periods (low certainty evidence). Adverse effects were reported in only one study; 11% and 21% developed postural hypotension on the low-salt diet and the low-salt diet combined with hydrochlorothiazide, respectively.
Authors' Conclusions: This systematic review shows an important reduction in SBP and DBP in people with diabetes with normal GFR during short periods of salt restriction, similar to that obtained with single drug therapy for hypertension. These data support the international recommendations that people with diabetes with or without hypertension or evidence of kidney disease should reduce salt intake to less than 5 g/day (2 g sodium).
(Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)

Update of: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006763. (PMID: 21154374)

J Clin Epidemiol. 2011 Apr;64(4):401-6. (PMID: 21208779)
Diabetes Care. 2001 Jan;24(1):111-6. (PMID: 11194215)
Diabetes Care. 2002 Jun;25(6):1072-7. (PMID: 12032117)
Diabetes Care. 1998 Apr;21(4):482-6. (PMID: 9571328)
Diabetologia. 1981 Sep;21(3):165-71. (PMID: 7028550)
Nutrients. 2018 Jun 06;10(6):. (PMID: 29882800)
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1653-1661. (PMID: 33838996)
Diabetes. 1998 Aug;47(8):1347-53. (PMID: 9703338)
Kidney Int. 2002 Mar;61(3):1086-97. (PMID: 11849464)
J Diabetes Investig. 2021 Feb;12(2):207-216. (PMID: 32597548)
Hypertension. 2001 Apr;37(4):1053-9. (PMID: 11304502)
Nephron. 1997;76(4):411-7. (PMID: 9274838)
Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. (PMID: 29104158)
J Am Soc Nephrol. 1997 May;8(5):749-55. (PMID: 9176844)
Lancet. 2019 May 11;393(10184):1958-1972. (PMID: 30954305)
BMJ. 2008 Apr 26;336(7650):924-6. (PMID: 18436948)
Nephrol Dial Transplant. 2016 Jul;31(7):1081-7. (PMID: 25744274)
Am J Physiol. 1987 Jan;252(1 Pt 2):F65-73. (PMID: 3812702)
Diabetologia. 1996 Feb;39(2):212-9. (PMID: 8635674)
Miner Electrolyte Metab. 1998;24(4):296-301. (PMID: 9554571)
J Am Soc Nephrol. 2013 Dec;24(12):2096-103. (PMID: 24204003)
Trials. 2019 Dec 23;20(1):761. (PMID: 31870424)
Kidney Int. 1997 Sep;52(3):771-7. (PMID: 9291199)
J Clin Med. 2020 Jul 08;9(7):. (PMID: 32650548)
Kidney Int Suppl. 1997 Dec;63:S198-200. (PMID: 9407458)
Nutrients. 2019 Sep 12;11(9):. (PMID: 31547438)
J Clin Endocrinol Metab. 1998 May;83(5):1552-7. (PMID: 9589654)
Circulation. 2002 Oct 1;106(14):1777-82. (PMID: 12356629)
Cochrane Database Syst Rev. 2020 Dec 12;12:CD004022. (PMID: 33314019)
Diabetologia. 2002 Apr;45(4):535-41. (PMID: 12032630)
Hypertension. 2005 Aug;46(2):308-12. (PMID: 15983240)
BMJ. 1991 Apr 6;302(6780):819-24. (PMID: 1827353)
Diabetologia. 1984 Nov;27(5):522-6. (PMID: 6096193)
Medicine (Baltimore). 2016 Nov;95(46):e5003. (PMID: 27861335)
J Hum Hypertens. 2009 Jun;23(6):363-84. (PMID: 19110538)
Cardiovasc Diabetol. 2018 Apr 18;17(1):57. (PMID: 29669543)
J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. (PMID: 27856633)
BMC Nephrol. 2012 Oct 19;13:137. (PMID: 23082956)
Int J Environ Res Public Health. 2021 Jun 28;18(13):. (PMID: 34203155)
J Hum Hypertens. 1996 Aug;10(8):517-21. (PMID: 8895035)
Am J Physiol. 1995 Aug;269(2 Pt 2):R380-8. (PMID: 7653660)
BMC Nephrol. 2014 Apr 04;15:57. (PMID: 24708818)
N Engl J Med. 2014 Aug 14;371(7):624-34. (PMID: 25119608)
BMJ. 1989 Jan 28;298(6668):227-30. (PMID: 2493869)
Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):531-4. (PMID: 3103761)
Hypertension. 2009 Sep;54(3):482-8. (PMID: 19620514)
Diabetes Care. 2002 Apr;25(4):663-71. (PMID: 11919122)
BMC Nephrol. 2016 Jul 19;17(1):88. (PMID: 27430216)
Hypertension. 2002 Jan;39(1):129-34. (PMID: 11799091)
Lancet Diabetes Endocrinol. 2014 May;2(5):385-95. (PMID: 24795252)
BMJ. 2000 Aug 12;321(7258):412-9. (PMID: 10938049)
Curr Opin Nephrol Hypertens. 2003 May;12(3):317-22. (PMID: 12698072)
Hypertension. 2006 Oct;48(4):519-26. (PMID: 16952978)
Diabetes Res Clin Pract. 2010 Feb;87(2):228-32. (PMID: 19889469)
N Engl J Med. 2021 Sep 16;385(12):1067-1077. (PMID: 34459569)
Kidney Int. 2020 Oct;98(4S):S1-S115. (PMID: 32998798)
Diabetes Care. 2009 Aug;32(8):1398-403. (PMID: 19549737)
Hypertension. 2003 Dec;42(6):1093-9. (PMID: 14610100)
J Hum Hypertens. 2002 Nov;16(11):761-70. (PMID: 12444537)
Am J Hypertens. 1999 Apr;12(4 Pt 1):348-55. (PMID: 10232494)
Hypertension. 2016 Jun;67(6):1189-95. (PMID: 27160199)
Diabetologia. 2004 Feb;47(2):300-3. (PMID: 14704836)
Diabetes. 1997 Jan;46(1):19-24. (PMID: 8971091)
Cochrane Database Syst Rev. 2021 Jun 24;6:CD010070. (PMID: 34164803)
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006763. (PMID: 21154374)
Contemp Clin Trials. 2018 Jan;64:265-273. (PMID: 28867396)
Nutr Metab Cardiovasc Dis. 2016 Aug;26(8):689-96. (PMID: 27266988)
J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583)
J Hum Hypertens. 2020 Feb;34(2):143-150. (PMID: 31501493)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)

ClinicalTrials.gov NCT00253786; NCT01967901; NCT01393808

0 (Sodium Chloride, Dietary)
9NEZ333N27 (Sodium)

Date Created: 20230116 Date Completed: 20230118 Latest Revision: 20240117

20240117

PMC9841968

10.1002/14651858.CD006763.pub3

36645291